ENOV vs. MLTX
ENOV (Enovis Corp) and MLTX (MoonLake Immunotherapeutics) are both stocks. ENOV operates in Specialty Industrial Machinery (Industrials), while MLTX operates in Biotechnology (Healthcare). Over the past 5 years, ENOV returned -22.84%/yr vs 12.70%/yr for MLTX. At a 0.12 correlation, their price movements are largely independent.
Performance
ENOV vs. MLTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ENOV achieves a -19.07% return, which is significantly lower than MLTX's 38.62% return.
ENOV
- 1D
- -1.73%
- 1M
- -7.63%
- YTD
- -19.07%
- 6M
- -26.37%
- 1Y
- -29.73%
- 3Y*
- -27.36%
- 5Y*
- -22.84%
- 10Y*
- -7.79%
MLTX
- 1D
- 2.24%
- 1M
- 4.04%
- YTD
- 38.62%
- 6M
- 36.85%
- 1Y
- -62.37%
- 3Y*
- -13.16%
- 5Y*
- 12.70%
- 10Y*
- —
ENOV vs. MLTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ENOV Enovis Corp | -19.07% | -39.29% | -21.67% | 4.67% | -32.36% | 20.21% | 21.01% |
MLTX MoonLake Immunotherapeutics | 38.62% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 8.39% |
Correlation
The correlation between ENOV and MLTX is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2020 | 0.12 |
Fundamentals
ENOV:
-$26.70
MLTX:
-$3.90
ENOV:
$2.28B
MLTX:
$0.00
ENOV:
$1.38B
MLTX:
-$1.49M
ENOV:
-$840.37M
MLTX:
-$179.84M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ENOV vs. MLTX — Risk / Return Rank
ENOV
MLTX
ENOV vs. MLTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Enovis Corp (ENOV) and MoonLake Immunotherapeutics (MLTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ENOV | MLTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.01 | ||
| Sortino ratioReturn per unit of downside risk | -1.22 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.17 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | -0.74 | -0.70 | -0.05 |
| Martin ratioReturn relative to average drawdown | -1.17 | -0.99 | -0.18 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ENOV | MLTX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.55 | -0.54 | -0.01 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.59 | 0.14 | -0.73 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.18 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.06 | 0.12 | -0.18 |
Drawdowns
ENOV vs. MLTX - Drawdown Comparison
The maximum ENOV drawdown since its inception was -83.36%, smaller than the maximum MLTX drawdown of -90.22%. Use the drawdown chart below to compare losses from any high point for ENOV and MLTX.
Loading charts...
Drawdown Indicators
| ENOV | MLTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.36% | -90.22% | +6.86% |
Max Drawdown (1Y)Largest decline over 1 year | -40.29% | -89.93% | +49.64% |
Max Drawdown (3Y)Largest decline over 3 years | -67.26% | -90.22% | +22.96% |
Max Drawdown (5Y)Largest decline over 5 years | -76.46% | -90.22% | +13.76% |
Max Drawdown (10Y)Largest decline over 10 years | -76.46% | — | — |
Current DrawdownCurrent decline from peak | -83.28% | -71.39% | -11.89% |
Average DrawdownAverage peak-to-trough decline | -45.92% | -29.15% | -16.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.34% | 62.80% | -37.46% |
Volatility
ENOV vs. MLTX - Volatility Comparison
Enovis Corp (ENOV) and MoonLake Immunotherapeutics (MLTX) have volatilities of 19.66% and 18.88%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ENOV | MLTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.66% | 18.88% | +0.78% |
Volatility (6M)Calculated over the trailing 6-month period | 39.94% | 56.83% | -16.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.08% | 117.11% | -63.03% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.61% | 91.12% | -52.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.30% | 86.52% | -44.22% |
Dividends
ENOV vs. MLTX - Dividend Comparison
Neither ENOV nor MLTX has paid dividends to shareholders.
Financials
ENOV vs. MLTX - Financials Comparison
This section allows you to compare key financial metrics between Enovis Corp and MoonLake Immunotherapeutics. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ENOV and MLTX have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ENOV has higher volatility (19.66%) compared to MLTX (18.88%). In terms of maximum drawdown, ENOV dropped -83.36% vs MLTX's -90.22%.
MLTX currently has the higher Sharpe Ratio (-0.54 vs -0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ENOV and MLTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer